Adicet Bio Inc (ACET) - News Archive

Adicet Bio Pioneers Allogeneic Gamma Delta T Cell Therapies as It Prepares to Showcase Breakthrough Findings at SITC 2025 In a transformative era for cancer therapy and autoimmune disease treatment, Adicet Bio, Inc. (Na...

Redwood City, Calif. & Boston In a significant development in the biotechnology sector, Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage biotechnology company specializing in the development of allogeneic gamma delta T...

Redwood City, CA & Boston In a significant development for patients suffering from systemic sclerosis (SSc), Adicet Bio, Inc. (Nasdaq: ACET), a pioneering clinical-stage biotechnology firm, has announced that the U.S. F...

Adicet Bio, Inc. a pioneering biotechnology firm focused on the development of allogeneic gamma delta T cell therapies, has made significant strides in the fight against cancer and autoimmune diseases with the recent in...

In the ever-evolving landscape of oncology, the race to find effective treatments for solid tumors remains an urgent challenge, particularly for metastatic and advanced clear cell renal cell carcinoma (ccRCC). Amidst th...

Adicet Bio, Inc. a clinical-stage biotechnology firm, is making strides in the field of allogeneic, gamma delta T cell therapies aimed at treating autoimmune diseases and cancer. In recent developments, the company pres...

Adicet Bio Unveils Promising Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy at ACR Convergence 2024 In a landmark moment for the field of immunotherapy, Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage bi...

Adicet Bio Secures FDA Approval for Pioneering Trials of ADI-001 in Rare Autoimmune Disorders: Idiopathic Inflammatory Myopathy and Stiff Person Syndrome to ADI-001 and Its Potential Impact In an exciting development fo...

In an era gleaming with the luminescent glow of scientific inquiry and medicinal advancement, Adicet Bio, Inc. domiciled in the fair hamlets of Redwood City and Boston, hath taken a momentous stride in the realm of biop...

: Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage biotechnology company, recently revealed compelling clinical biomarker data from the ongoing Phase 1 GLEAN trial of ADI-001. This novel allogeneic gamma delta T cell t...

In recent groundbreaking developments, Adicet Bio, a clinical stage biotechnology company specializing in allogeneic gamma delta T cell therapies, has received significant recognition and support from the U.S. Food and...

CSIMarket.com Adicet Bio, Inc. (Nasdaq: ACET), a prominent clinical-stage biotechnology company, has carved out a distinct place in the fields of cancer and autoimmune disease treatment through its pioneering work on al...

Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis and Reports Promising First Quarter Financial Results (Title Suggestions: Adicet Bio s ADI-001 Receives FDA Fast Track Designation for Lupus...

Redwood City, Calif. & Boston In a strategic move to fortify its research and development capabilities, Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage biotechnology company specializing in allogeneic gamma-delta T ce...

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) New Inducements: A Strategic Step Towards Visionary Growth at Adicet Bio, Inc.Adicet Bio, Inc. (Nasdaq: ACET), renowned for its pioneering work i...

Adicet Bio Poised for Transformational Year in 2024: First Quarter Financial Results and Business Updates By REDWOOD CITY, Calif. & BOSTON Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage biotechnology company at the f...

Adicet Bio, Inc., a leading biotechnology firm specializing in the discovery and development of allogeneic gamma delta T cell therapies for cancer and autoimmune diseases, recently unveiled groundbreaking preclinical da...